Last Price
0.331
Today's Change
-0.014 (4.05%)
Day's Change
0.33 - 0.36
Trading Volume
478,622
Market Cap
1 Million
Shares Outstanding
374 Million
Avg Volume
16,415,728
Avg Price (50 Days)
0.36
Avg Price (200 Days)
0.48
PE Ratio
-0.34
EPS
-0.01
Earnings Announcement
10-Jun-2026
Previous Close
0.34
Open
0.33
Day's Range
0.33 - 0.36
Year Range
0.22 - 0.875
Trading Volume
478,622
1 Day Change
0.00%
5 Day Change
-1.43%
1 Month Change
-16.87%
3 Month Change
46.81%
6 Month Change
-42.50%
Ytd Change
-5.48%
1 Year Change
-48.89%
3 Year Change
-96.58%
5 Year Change
-98.59%
10 Year Change
-97.70%
Max Change
-99.99%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
{uid}
{comment}
Just now